What your G2083 actually pays: Medicare's 2026 rate for the higher Spravato dose

The higher-dose esketamine code pays more than any other single code in this series, more than eight times what a standard 60-minute therapy session pays. Medicare raised it 15.8% for 2026, and the same two-hour monitoring rule applies regardless of dose.

The code, and how it differs from G2082

HCPCS code G2083 covers an office visit for esketamine (Spravato) administration and monitoring at a dose above 56 milligrams, the higher end of the Food and Drug Administration (FDA)-approved dosing range for treatment-resistant depression. Like its lower-dose sibling G2082, it bundles the drug, the supervised self-administration, and the mandatory two-hour post-dose monitoring required under the Risk Evaluation and Mitigation Strategy (REMS) program into a single payment. The monitoring requirement itself does not change with dose; a patient at 84 mg is watched for the same two hours as a patient at 56 mg. What changes is the quantity of drug the payment has to cover, which is why G2083 pays substantially more.

What Medicare pays in 2026

Medicare pays $1,356.08 nationally for G2083 in 2026, up from $1,171.27 in 2025, an increase of 15.8%, the largest percentage gain of any code in this series, just ahead of G2082 at 15.4%. In dollar terms it is also the largest single code in the entire family we have covered: $184.81 more per visit than last year, on a base that already pays more than eight standard therapy hours combined.

As with G2082, the increase outpaces the 3.26% rise in the Medicare conversion factor by a wide margin, consistent with a specific update to the drug-cost input CMS uses to price the code rather than the general fee schedule mechanics affecting office-visit and therapy codes this year.

A note on billing this commercially

Like G2082, G2083 is a Medicare-specific construct. Commercial payers generally price esketamine through a separate drug code and monitoring visit rather than this bundled structure, and PayerPrice has no listing for it. We are not publishing a commercial figure for G2083 because no adequately sourced one exists; a practice negotiating commercial esketamine rates should request the payer's actual coding methodology rather than assume it mirrors Medicare's bundle.

The so-what

• Verify the dose before selecting the code. The 56 mg threshold is the entire difference between G2082 and G2083; a documentation error here is a coding error with a four-figure swing.
• Confirm authorization covers the actual dose band. A prior authorization approved for standard dosing may not automatically extend to a patient titrated up to the G2083 range; check before the visit, not after the claim is denied.